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Abstract
Background: Vectors based on adeno-associated virus-8 (AAV8) have shown efficiency and
efficacy for liver-directed gene therapy protocols following intravascular injection, particularly in
relation to haemophilia gene therapy. AAV8 has also been proposed for gene therapy targeted at
skeletal and cardiac muscle, again via intravascular injection. It is important to assess vector
targeting at the level of virion accumulation and transgene expression in multiple species to
ascertain potential issues relating to species variation in infectivity profiles.
Methods: We used AAV8 vectors expressing human factor IX (FIX) from the liver-specific LP-1
promoter and administered this virus via the intravascular route of injection into 12 week old
Wistar Kyoto rats. We assessed FIX levels in serum by ELISA and transgene expression at sacrifice
by immunohistochemistry using anti-FIX antibodies. Vector DNA levels in organs we determined
by real time PCR.
Results: Administration of 1 × 1011 or 5 × 1011 scAAV8-LP1-hFIX vector particles/rat resulted in
efficient production of physiological hFIX levels, respectively in blood assessed 4 weeks post-
injection. This was maintained for the 4 month duration of the study. At 4 months we observed
liver persistence of vector with minimal non-hepatic distribution.
Conclusion: Our results demonstrate that AAV8 is a robust vector for delivering therapeutic
genes into rat liver following intravascular injection.
Background
Adeno-associated viruses (AAV) are attractive vectors for
in vivo gene therapy due to their safety profile and ability
to achieve long term production of therapeutic genes fol-
lowing cell infection. Intravascular delivery provides a
minimally invasive yet versatile approach to gene therapy
for applications to correct liver deficiencies or utilise this
organ for production of therapeutic genes. AAV serotype 2
(AAV2) has been studied in detail preclinically with suc-
cess [1-5], however, this vector generates a cytotoxic T-cell
response as evidenced in human subjects on a haemo-
philia trial leading to transient transaminitis and only
short term FIX production [6]. Alternate AAV vectors are
being pursued for gene therapy to overcome limitations in
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the efficiency of AAV2-mediated gene delivery to the liver
[7]. AAV8 in particular shows promise in this regard since
it is less immunogenic than AAV-2 capsids [8]. AAV8 has
been shown to have improved liver transduction effi-
ciency in murine models of 10–100 fold increase over
AAV2 vectors [9] and rapid uncoating post-internalisation
overcomes additional limitations of AAV2 [10]. A number
of studies have already assessed the potential of AAV8
using mouse and non-human primate models for haemo-
philia gene therapy and application to muscular dystro-
phy [11-14]. Importantly, it has been demonstrated that
peripheral venous administration is as effective as the
direct intraportal route of vector administration in animal
models suggesting profound liver targeting capacity [13].
In addition, Wang et al demonstrated the long-term effi-
cacy and safety of the AAV2/8 vector in liver-directed gene
therapy in dogs [15]. The application of the vector to gene
therapy is therefore dictated by the tropism observed fol-
lowing administration by a particular route of administra-
tion. Subtle differences between species can have a large
impact on efficiency and safety. No studies to date have
addressed AAV2/8 biodistribution or transgene expres-
sion following iv delivery in rats, a particularly important
model for many pre-clinical diseases. This study therefore
sought to quantify both parameters following peripheral
vein injection into adult male Wistar Kyoto rats. We used
an AAV8 pseudotyped self-complementary AAV vector,
with the liver-specific enhancer/promoter LP1 driving
expression of the reporter gene hFIX [11,12] and assessed
biodistribution, transgene expression and longevity of
expression.
Methods
Animals
Animal procedures were performed in accordance with
UK Home Office Animals (Scientific) Procedure Act 1986,
UK and Personal Licences regulations. scAAV8-LP1-hFIX
vector at doses ranging from 1010vg/rat to 5 × 1011vg/rat
were administered to 12 week old Wistar Kyoto rats (n =
3/group) via femoral vein injection.
Vectors
The construction and production of this vector was
described previously [12]. Briefly, scAAV8-LP1-hFIX was
constructed using a recombinant AAV2 vector backbone
incorporating an expression cassette with the human fac-
tor IX gene and driven by a liver-specific enhancer/pro-
moter LP1, and subsequently cross-packaged as a dimer
into the AAV8 capsid protein. The scAAV8 pseudotyped
vector was produced by the triple transient transfection
method and purified by ion exchange chromatography.
Vector genome titres were determined by the previously
described quantitative slot-blot method using supercoiled
plasmid DNA as standards [16].
Quantitative analysis of vector DNA from tissues of 
scAAV8-LP1-hFIX infused rats to determine biodistribution 
profile of rAAV8 vector
Four months after vector infusions animals were sacrificed
and tissues immediately snap frozen in liquid nitrogen
then stored at -70°C. DNA concentrations were quanti-
fied by spectrophotometry and 100 ng of purified DNA
from each tissue sample obtained was used in a Sybr
Green PCR assay, with 200 nmol/L of sense (5'-TTTCCT-
GATGTGGACTATGT-3') and 200 nmol/L of anti-sense
primer (5'-TCATGGAAGCCAGCACAGAACATG-3'), to
quantify vector DNA by TaqMan PCR (Perkin-Elmer,
Applied Biosystems, Foster City, California). A human FIX
quantification standard curve was generated from 10-fold
serial dilutions of scAAV8-LP1-hFIX preparation. Target
template serial dilutions and all experimental samples
were run in duplicate. The following reaction conditions
were used: denaturation, 95°C for 10 minutes; amplifica-
tion, 95°C for 15s, 60°C for 1 min (40 cycles); dissocia-
tion, 95°C for 15s, 60°C for 15s, 95°C for 15s using a
7900HT ABI Prism Sequence Detection System. Data were
processed by the SDS 2.1 software package (Perkin-Elmer,
Applied Biosystems).
Determination of circulating human factor IX levels in 
blood plasma of scAAV8-LP1-hFIX infused rats
Blood samples were collected at days 0, 3, 7, 14, 28, 56,
112 days post injection into citrate buffer (9 parts blood:
1 part anti-coagulant) from the saphenous vein by veni-
puncture, starting prior to vector administration to obtain
baseline measurements, throughout the study and then a
final bleed by cardiac puncture at 4 months when rats
were sacrificed. Citrate buffered blood samples were cen-
trifuged at 2000 g for 15 minutes then the plasma was col-
lected and subsequently assayed by anti-FX ELISA [12] to
measure circulating hFIX activity.
Histological analysis of human FIX expression in livers of 
scAAV8-LP1-hFIX infused rats
At 4 months after vector infusions pieces of rat liver lobes
were fixed for 16 hours in 10% formalin. Formalin fixed,
paraffin embedded specimens were sectioned at 6 μm
using a microtome (Shandon Finesse 325, Thermo Elec-
tron Co.). Heart tissues were also collected and processed
in the same way and used as negative controls for human
FIX expression. Sections were deparaffinised and rehy-
drated in an alcohol concentration gradient then endog-
enous peroxidase activity was quenched by incubating the
sections in 0.3% hydrogen peroxide in methanol for 30
minutes. Unmasking of the antigen was performed using
Target Retrieval Solution as per the recommendations of
the manufacturer (Dako Cytomation Ltd, UK) then sec-
tions were blocked in PBS for 30 minutes before proceed-
ing with staining.Genetic Vaccines and Therapy 2008, 6:9 http://www.gvt-journal.com/content/6/1/9
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Human FIX expression in tissue sections was analysed by
immunohistochemistry using a 1:100 dilution (10 μg/ml)
of goat anti-human FIX-HRP antibody (Affinity Biologi-
cals). The negative control was goat IgG used at 10 μg/ml
and anti-goat IgG HRP conjugated antibody at 1:10000
(Dako Cytomation Ltd, UK). The primary antibody was
incubated overnight at 4°C and the secondary antibody
was incubated at room temperature for 1 hour. Diami-
nobenzidine (DAB) chromagen solution (Dako Cytoma-
tion Ltd, UK) was used to detect horse radish peroxidase
activity (positive staining shows as brown) and cell nuclei
were counterstained in haematoxylin. Sections were dehy-
drated through an ethanol gradient and mounted in Hist-
omount (Invitrogen). Images were captured by a Hitachi
HVC2OA camera attached to an Olympus ×40 micro-
scope.
Results and Discussion
We examined the transduction efficiency and biodistribu-
tion profile of scAAV8LP1hFIX in 12 week old male Wister
Kyoto rats 4 months following a single systemic injection
of the vector via the femoral vein at doses of between
1010vg/rat to 5 × 1011vg/rat or saline control (n = 3 rats per
group). The tissue distribution (measured by Taqman™
realtime PCR) of the scAAV8-LP1-hFIX virus was strongly
restricted to the liver with virtually no detectable virion
accumulation in any other organ (Figure 1). This demon-
strates a strong hepatic targeting of AAV8 in a dose
dependent manner and was evident at all doses tested
(Figure 1). Although the liver is clearly the predominant
site for virion sequestration, the pattern in rats is modestly
different to both mouse and non-human primates [11-
13]. In mice significant levels of virion accumulation were
Quantitative analysis of vector biodistribution following  intravascular administration of AAV8LP-1FIX into rats Figure 1
Quantitative analysis of vector biodistribution following intravas-
cular administration of AAV8LP-1FIX into rats. DNA was 
extracted and processed from tissues of rats, which were dissected 4 
months after intravenous injections of scAAV8-LP1-hFIX. Purified DNA 
was subsequently analysed by quantitative real-time PCR using hFIX spe-
cific primers designed to hybridise to the human FIX coding region of the 
AAV8 vector.12. Data are presented as the means ± standard error of the 
mean. VG = vector genomes.
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Determination of circulating human factor IX levels in blood plasma of AAV8hFIX infused rats Figure 2
Determination of circulating human factor IX levels in blood plasma of AAV8hFIX infused rats. Blood plasma samples from scAAV8-LP1-hFIX 
infused rats at (black sqaure) 1 × 1010vg/rat, (black triangle) 5 × 1010vg/rat, (open triangle) 1 × 1011vg/rat, (open square) 5 × 1011vg/rat or (black circle) 
saline were assayed by ELISA to measure circulating hFIX activity. All values represent average hFIX levels with standard error of mean. Percentages refer 
to the percentage of normal circulating FIX levels.
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detected in kidney and lungs in addition to liver [13]. In
monkeys the majority was localised to liver but splenic
accumulation was also observed [13].
To determine the level of transgene expression circulating
in the blood following scAAV8 delivery in rats we per-
formed enzyme-linked immunosorbent assay specific for
hFIX on plasma samples taken from rats over the course
of the experiment (4 months). Human FIX was detectable
in the blood within 3 days and continued to rise until
reaching peak levels at 4 weeks, with values of approxi-
mately 2.9 ± 0.26 μg/ml, 0.7 ± 0.2 μg/ml, 0.3 ± 0.06 μg/
ml and 0.03 ± 0.01 μg/ml with administration of 5 × 1011,
1 × 1011, 5 × 1010, and 1 × 1010 vector genomes/rat, respec-
tively (Figure 2). The plasma concentration of hFIX
achieved from a single intravenous injection of 5 × 1011
vg/rat scAAV8-LP1-hFIX produced over 40% physiologic
level in just 4 weeks. Infusion of lower doses of 1 × 1011
and 5 × 1010vg/rat scAAV8-LP1-hFIX produced moderate
increases in circulating transgene expression. The differ-
ence in transgene expression between vector doses was
highly significant (P < 0.0001, by one-way ANOVA) dem-
onstrating a dose response throughout the dosing regi-
mens employed.
Immunohistochemical staining of the liver after intrave-
nous administration of scAAV8-LP1-hFIX at doses of 1 ×
1011 and 5 × 1011 vg/rat showed expression of hFIX in the
hepatocytes at 16 weeks that was substantially higher than
hFIX expression in the hepatocytes from rats infused with
the lower doses of 1 × 1010 and 5 × 1010 vg/rat (Figure 3).
A clear gradient in expression is seen with the most effi-
ciently transduced cells around the portal tract (Figure 3),
consistent with observations in mice [13]. No expression
was seen in the heart of any of the animals by hFIX stain-
ing (data not shown), again confirming the hepatic selec-
tivity of this vector construct.
Conclusion
In summary, we have demonstrated herein that AAV8 can
be used to mediate long term stable expression of trans-
gene at therapeutic levels in the rat. This study confirms
those conducted in other species relating to the strong
hepatic tropism of AAV2/8 following peripheral vein
injection and underscores the utility of this virus for gene
therapy applications targeted to the liver.
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